News Pfizer breast cancer drug Ibrance rejected by NICE Ibrance too expensive at almost £80,000 per course.
News Pfizer looks to M&A after results disappointment Pfizer is looking to deals to keep investors onside after a disappointing set of Q4 results.
News Don't cut prices, cut taxes, pharma CEO tells Trump Industry plays key role in job creation too, says Novartis CEO.
News Pfizer, Novo invest in Swedish patient stratification startu... Funds will go towards development of AMRA's body composition profiling tool AMRA Profiler.
News Pharma project aims to help doctors find drug info Industry giants such as AstraZeneca and Novartis are on board.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.